IDRA
Editado
Nuestros expertos médicos varios que le echen un vistazo a los fundamentos médicos de esta. A mí de entrada me parece bastante mona, y a David imagino que le gusta por técnico, dado que la ha mentado. Lo del Russell y que anunciará inicio de ensayo pronto son sus dos bazas actuales.
Enfocada en las enfermedades autoinmunes raras.
Todo hostias previas en sus compuestos previos (para cáncer y hepatitis C), pero el nuevo compuesto IMO-8400 ha demostrado seguridad de la dosis y efectividad en el tratamiento de la soriasis sin reacciones adversas
Espera probarse en miositis, linfoma de células B y otras enfermedades autoinmunes huérfanas.
http://www.fiercebiotech.com/story/idera-spikes-its-and-down-tlr-program-comes-through-phii/2014-03-28
Oferta pública de acciones a 4 de febrero de 2014. En el último informe dicen que tienen pasta hasta 2016. (Habría que salir como tarde en febrero del año que viene. En 2013 habían avisado de que tenían pasta hasta finales de 2014 e hicieron la dilución en febrero, y ahora tienen previsto meterse con varios ensayos a la vez).
Dice que inicia ensayo para antes de fin de año, puede ser buena oportunidad y más como fármaco huérfano.
Efectivamente, está reclutando enfermos para la macroglobulinemia de Waldenstrom (MW, también conocida como linfoma linfoplasmático)
https://clinicaltrials.gov/ct2/show/NCT02092909
y tienen el de la soriasis aún abierto:
http://clinicaltrials.gov/ct2/show/NCT01899729?term=Idera+Pharmaceuticals&rank=5
Relaciones con Abbot:
for the development of an in vitro companion diagnostic test for use in Idera's clinical development programs to treat certain genetically defined forms of B-cell lymphoma with IMO-8400.Under the agreement, Abbott will develop a test utilizing polymerase chain reaction (PCR) technology to identify the presence of the MYD88 L265P oncogenic mutation in tumor biopsy samples with high sensitivity and specificity
http://www.reuters.com/finance/stocks/IDRA.O/key-developments/article/2985588
y la Myositis Association:
“TMA is very pleased to collaborate with Idera to help advance their novel TLR antagonist therapeutic approach in myositis,” said Bob Goldberg, Executive Director of The Myositis Association. “We believe that the work Idera is doing will further the myositis medical field and our understanding of how to better treat patients suffering from this debilitating rare disease.”
Polymyositis and dermatomyositis are devastating, rare inflammatory myopathies that cause inflammation and progressive weakness in muscles. Polymyositis and dermatomyositis patients can develop serious disabilities, including loss of mobility, difficulty breathing and swallowing, and have an increased risk of certain cancers. Dermatomyositis is also accompanied by a purple or red skin rash. There are an estimated 15,000 polymyositis patients and 25,000 dermatomyositis patients in the U.S. alone. Both polymyositis and dermatomyositis have been designated as rare diseases by the U.S. Food and Drug Administration (FDA).
Añadida al Russell 3000 y Microcap en la actualización de junio de 2014.
Pipeline: http://www.iderapharma.com/our-clinical-programs
Resumen del segundo trimestre de 2014
http://www.twst.com/update/75366-idera-pharmaceuticals-inc-idera-pharmaceuticals-reports-second-quarter-2014-financial-results-and-provides-corporate-update
Fundamentos del ensayo de psoriasis
Idera’s approach to the potential treatment of autoimmune and inflammatory diseases involves inhibiting the induction of immune responses mediated through Toll-like Receptor (TLR) 7, TLR8 and TLR9. These TLRs are known to be activated in autoimmune and inflammatory diseases by aberrant complexes that contain host RNA or DNA. The Company has two clinical-stage TLR antagonist drug candidates.
is an antagonist of TLR7, TLR8 and TLR9.
The Company initiated a Phase 1 clinical trial of IMO-8400 in the fourth quarter of 2012 to assess the safety and the pharmacodynamic activity of IMO-8400 in healthy subjects. The single-dose portion of this trial involved three escalating dose levels of 0.1, 0.3 and 0.6 mg/kg of IMO-8400 or placebo, with six subjects receiving each treatment, and was completed during the first quarter of 2013. IMO-8400 treatment was well-tolerated at all dose levels, and the intended target engagement of TLR7, TLR8 and TLR9 was observed in IMO-8400-treated subjects compared to placebo-treated subjects.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
